NextFin News - Eli Lilly is preparing to deploy its massive cash reserves from the GLP-1 weight-loss boom into increasingly diverse therapeutic areas, signaling a strategic shift away from its current reliance on obesity and diabetes treatments. Jake Van Naarden, President of Lilly Oncology and the company’s head of business development, indicated on Wednesday that the pharmaceutical giant is actively seeking acquisitions that would push the firm into entirely new clinical territories. The comments come as Lilly’s revenue from GLP-1 therapies reached $36.5 billion in 2025, accounting for more than half of its $65.18 billion total annual revenue.
Van Naarden, who has led Lilly’s oncology unit since 2021 and took over the broader business development mantle shortly thereafter, has historically favored high-science, platform-based acquisitions over late-stage commercial assets. Under his tenure, Lilly has moved aggressively into genetic medicines and cell therapies, often paying significant premiums for early-stage technology. His recent remarks suggest that the "GLP-1 windfall" is now being treated as a strategic catalyst to insulate the company against future patent cliffs and the eventual plateauing of the obesity market.
The scale of this diversification is already visible in the company’s 2026 deal ledger. Earlier this year, Lilly committed up to $7 billion for Kelonia Therapeutics, an in-vivo CAR-T technology firm, and another $2.4 billion for Orna Therapeutics. These deals focus on autoimmune diseases and multiple myeloma—sectors far removed from the metabolic health core that currently drives Lilly’s trillion-dollar valuation. By targeting in-vivo CAR-T, Van Naarden is betting on "off-the-shelf" cell therapies that could bypass the complex manufacturing hurdles that have limited the commercial success of first-generation treatments.
While the market has largely rewarded Lilly’s expansionist strategy, some analysts remain cautious about the execution risks inherent in such a broad pivot. The acquisition of Kelonia, for instance, involves a $3.25 billion upfront cash payment for a platform that has yet to produce a commercialized product. This "platform-first" approach, while potentially transformative, carries a higher failure rate than acquiring mid-to-late-stage clinical assets. Skeptics argue that the current pace of M&A may lead to over-extension, particularly as the company simultaneously manages the massive capital expenditure required to scale its global manufacturing footprint for Zepbound and Mounjaro.
The urgency behind Van Naarden’s dealmaking is underscored by the looming "patent cliff" facing the broader pharmaceutical industry toward the end of the decade. Although Lilly’s incretin franchise is currently protected, the company is acutely aware of the need to build a "post-GLP-1" identity. The current strategy mirrors the historical patterns of other "one-drug" giants, such as AbbVie’s diversification beyond Humira, though Lilly is attempting this transition while its primary engine is still in its high-growth phase. The success of this strategy will depend on whether Van Naarden’s high-science bets can deliver clinical results before the market’s appetite for obesity-driven growth begins to wane.
Explore more exclusive insights at nextfin.ai.
